Keywords: Biogen Idec, Multiple sclerosis, MS, Oral drug candidate, BG-12, USA, FDA

Biogen Idec files oral MS candidate in USA

Article | 01 March 2012

Print This

US biotech firm Biogen Idec (Nadaq: BIIB) has submitted its orally-active drug for relapsing-remitting multiple sclerosis BG-12 with the Food ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in